Russian drug manufacturer Biocad has launched legal action against pharmaceutical giant Roche, accusing it of "sabotaging competition" by "deliberately" hiking prices in the US, while dropping the prices of Avastin, Herceptin, and Rituxan/MabThera in Russia, where Biocad was its selling biosimilar drugs. Biocad, in fact, charged Roche and Genentech gradually increased prices over the past few years in the US, while simultaneously lowering prices in Russia as part of its maneuvering to fend off biosimilar competition. The lawsuit, filed recently in New York, claimed Roche and its Genentech unit were "engaged in predatory pricing" to prevent Biocad from entering the market. In a statement, Roche's chief executive officer David Taylor said that he had been informed about the lawsuit on Friday morning.
Russian drug manufacturer Biocad has launched legal action against pharmaceutical giant Roche, accusing it of "sabotaging competition" by "deliberately" hiking prices in the US, while dropping the prices of Avastin, Herceptin, and Rituxan/MabThera in Russia, where Biocad was its selling biosimilar drugs. The lawsuit, filed recently in New York, claimed Roche and its Genentech unit were "engaged in predatory pricing" to prevent Biocad from entering the market. In a statement, Roche's chief executive officer David Taylor said that he had been informed about the lawsuit on Friday morning.